AIRLINK 73.43 Decreased By ▼ -6.57 (-8.21%)
BOP 5.13 Decreased By ▼ -0.05 (-0.97%)
CNERGY 4.38 Decreased By ▼ -0.08 (-1.79%)
DFML 34.30 Decreased By ▼ -0.86 (-2.45%)
DGKC 75.83 Decreased By ▼ -1.05 (-1.37%)
FCCL 19.85 Decreased By ▼ -0.13 (-0.65%)
FFBL 36.40 Increased By ▲ 0.80 (2.25%)
FFL 9.36 Decreased By ▼ -0.17 (-1.78%)
GGL 9.92 Decreased By ▼ -0.24 (-2.36%)
HBL 116.65 Decreased By ▼ -0.35 (-0.3%)
HUBC 132.79 Increased By ▲ 0.29 (0.22%)
HUMNL 7.10 Increased By ▲ 0.04 (0.57%)
KEL 4.52 Decreased By ▼ -0.13 (-2.8%)
KOSM 4.49 Decreased By ▼ -0.16 (-3.44%)
MLCF 36.50 Decreased By ▼ -1.00 (-2.67%)
OGDC 135.02 Increased By ▲ 0.55 (0.41%)
PAEL 22.72 Decreased By ▼ -0.18 (-0.79%)
PIAA 26.59 Decreased By ▼ -0.04 (-0.15%)
PIBTL 6.63 Decreased By ▼ -0.18 (-2.64%)
PPL 116.80 Increased By ▲ 4.70 (4.19%)
PRL 27.30 Increased By ▲ 0.10 (0.37%)
PTC 14.39 Increased By ▲ 0.01 (0.07%)
SEARL 55.45 Decreased By ▼ -0.94 (-1.67%)
SNGP 67.65 Increased By ▲ 0.65 (0.97%)
SSGC 10.80 Decreased By ▼ -0.03 (-0.28%)
TELE 8.70 Decreased By ▼ -0.59 (-6.35%)
TPLP 10.98 Decreased By ▼ -0.20 (-1.79%)
TRG 65.75 Decreased By ▼ -3.25 (-4.71%)
UNITY 25.06 Decreased By ▼ -0.43 (-1.69%)
WTL 1.32 No Change ▼ 0.00 (0%)
BR100 7,521 Decreased By -1.2 (-0.02%)
BR30 24,432 Increased By 30.1 (0.12%)
KSE100 71,768 Increased By 73.1 (0.1%)
KSE30 23,606 Increased By 64.3 (0.27%)

Merck & Co said on Monday the US Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on the treatment's effectiveness.

Merck said it would meet with the agency to discuss the next steps on the oral drug, gefapixant.

Shares in the company were down about 0.5% at $79.6 before the bell.

If approved later, gefapixant would become the first such remedy for patients who have a persisting cough after the treatment of underlying health conditions such as asthma or if they have an unexplained chronic cough, Merck said.

India says safety concerns restricting use of Merck COVID pill

Last week, Japan's health regulator approved gefapixant tablets for adults with refractory or unexplained chronic cough, to be marketed under the brand name Lyfnua.

The FDA's decision was not related to the drug's safety, Merck said.

Comments

Comments are closed.